Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • All Public Company
      • English-only
      • News Releases Overview

      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
      • Multimedia Gallery Overview

      • Trending Topics

      • All Trending Topics
  • Business & Money
      • Auto & Transportation

      • All Automotive & Transportation
      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • Auto & Transportation Overview

      • View All Auto & Transportation

      • Business Technology

      • All Business Technology
      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • Business Technology Overview

      • View All Business Technology

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Financial Services & Investing

      • All Financial Services & Investing
      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • Financial Services & Investing Overview

      • View All Financial Services & Investing

      • General Business

      • All General Business
      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • General Business Overview

      • View All General Business

  • Science & Tech
      • Consumer Technology

      • All Consumer Technology
      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • Consumer Technology Overview

      • View All Consumer Technology

      • Energy & Natural Resources

      • All Energy
      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • Energy & Natural Resources Overview

      • View All Energy & Natural Resources

      • Environ­ment

      • All Environ­ment
      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • Environ­ment Overview

      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • All Heavy Industry & Manufacturing
      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • Heavy Industry & Manufacturing Overview

      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • All Telecomm­unications
      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • Telecomm­unications Overview

      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • All Consumer Products & Retail
      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • Consumer Products & Retail Overview

      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Health

      • All Health
      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • Health Overview

      • View All Health

      • Sports

      • All Sports
      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • Sports Overview

      • View All Sports

      • Travel

      • All Travel
      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • Travel Overview

      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • All Policy & Public Interest
      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • Policy & Public Interest Overview

      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • All People & Culture
      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • People & Culture Overview

      • View All People & Culture

      • In-Language News

      • Arabic
      • español
      • português
      • Česko
      • Danmark
      • Deutschland
      • España
      • France
      • Italia
      • Nederland
      • Norge
      • Polska
      • Portugal
      • Россия
      • Slovensko
      • Suomi
      • Sverige
  • Overview
  • Distribution by PR Newswire
  • AI Tools
  • Investor Relations
  • Guaranteed Paid Placement
  • SocialBoost
  • All Products
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Hamburger menu
  • PR Newswire: news distribution, targeting and monitoring
  • Send a Release
    • ALL CONTACT INFO
    • Contact Us

      888-776-0942
      from 8 AM - 10 PM ET

  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • News in Focus
    • Browse All News
    • Multimedia Gallery
    • Trending Topics
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • Overview
  • Distribution by PR Newswire
  • AI Tools
  • Investor Relations
  • SocialBoost
  • All Products
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS

CITY HILL ARTS TO PRODUCE INCREDIBLE MEDICAL THRILLER "CHASING MY CURE" BASED ON LIFE OF DR. DAVID FAJGENBAUM


News provided by

City Hill Arts

Apr 17, 2025, 16:01 ET

Share this article

Share toX

Share this article

Share toX

-Academy Award Winning Producer Wendy Finerman collaborates with Former Star Quarterback turned Pioneering Doctor and entrepreneur Jonathan E. Lim for inspirational Medical Drama-

LOS ANGELES, April 17, 2025 /PRNewswire/ -- City Hill Arts, the film and media production and financing company founded by biotech entrepreneur Jonathan E. Lim, M.D., has optioned and immediately put into development Chasing My Cure, a project based on the true story of David Fajgenbaum, a former star quarterback-turned-medical student who began a furious charge to save his own life when he was diagnosed with a rare and usually fatal illness.

The story centers on Fajgenbaum, once a beast-like Georgetown quarterback and now a brilliant medical student, who is struck down with a fatal disease and given only six months to live. With no known cure, he gathers together an unconventional team to challenge every presumption of the medical establishment in a race to save his own life.

Today, Dr. Fajgenbaum is a leader in the medical community. Dr. Fajgenbaum and his team at Every Cure and the University of Pennsylvania were recently chronicled in the New York Times for their work using AI to repurpose existing medications to treat rare diseases.

Chasing My Cure will be written by Amy Snow and produced by Academy Award winning producer Wendy Finerman and Robin Jonas alongside Lim. The film will be executive produced by Steven P. Wegner and Lisa Zupan.

"I am so thankful to be alive and to be able to share my story with the world, but I never could have dreamed that it would end this way," said Dr. Fajgenbaum. "Going through it, the experience felt pretty similar to a movie thriller—the same drop in your stomach, the same fear about how it's all going to turn out. And, at times, I lost all hope, but also, like a movie, I kept grinding and believing it would work out—and that is what I hope will make this movie gripping and inspiring for audiences."

"Chasing My Cure is precisely the kind of movie we are pursuing at City Hill Arts—a story of someone doing something extraordinary," added Dr. Lim. "The fact that there's a medical and biotech angle to the story is certainly a plus, given that we know that world so well. But audiences will connect with the unwavering determination to live, and the love and ingenuity that helped make it possible, that defines David's story. He's an incredible individual and a true movie hero."

The deal was negotiated by Glenn Feig from Reder & Feig, LLP for City Hill Arts, and by Brooke Erlich from CAA and Jeffrey Smith from Greenberg Traurig, LLP for David Fajgenbaum.

Amy Snow is currently writing/directing a six episode series for Pinnacle Productions/Sony for Pure Flix based on the book Always Watching by Chevy Stevens. Her feature Strong Fathers, Strong Daughters just came out on Pure Flix. Snow also adapted the romantic comedy I Owe You One for Hello Sunshine, based on the best-selling book by Sophie Kinsella. 

Independent film and television producer Wendy Finerman founded Wendy Finerman Productions in 1988. In 1994, she became the first solo female producer in the history of the Academy of Motion Picture Arts and Sciences to have received an Oscar for Best Picture for Forrest Gump. Her extensive list of credits includes Fairy Tale –A True Story which earned her a BAFTA Award for Best Children's Film, P.S. I Love You, Drumline, Stepmom, and Academy Award nominated The Devil Wears Prada. Collectively, all of her films have grossed over 1.6 billion dollars in international theatrical release and earned 160 award nominations. Her next film is The Devil Wears Prada 2.

David Fajgenbaum, MD, MBA, MSc, is Co-Founder and President of Every Cure and a physician-scientist at the University of Pennsylvania where he is one of the youngest faculty members to receive tenure at Penn Medicine. He's also a patient battling a deadly disease for which he discovered a lifesaving treatment by repurposing an existing drug, an experience he recounted in his national bestselling memoir, 'Chasing My Cure'. Determined to unlock more hidden cures in FDA-approved medications, David has advanced 13 more repurposed treatments for diseases they weren't originally intended to treat. He recently co-founded Every Cure to accelerate the search for repurposed treatments and is pioneering a new field called "computational pharmacophenomics," which uses AI to systematically match all drugs with additional diseases they may treat. The U.S. government and the TED Audacious Project have announced more than $100 million in funding to power this transformative vision.

One of the youngest ever awardees of multiple top NIH and FDA grants, David has published over 100 scientific papers in leading journals, such as The New England Journal of Medicine, The Lancet, and the Journal of Clinical Investigation, which included a paper selected as one of the top innovations in science and medicine of 2020. He has been profiled by The New York Times, TODAY, GMA, USA TODAY, and Forbes 30Under30 and awarded the 2016 Atlas Award alongside then VP Joe Biden, 2022 NDRI Service to Science Award alongside Nobel Laureates Katalin Kariko and Drew Weissman, 2023 Philadelphia Citizen of the Year Award, and 2024 WebMD Health Hero Award.

ABOUT CITY HILL ARTS

City Hill Arts is a film production and finance venture seeking to revitalize people, planet and perspective. The focus is on compelling, character-driven stories from diverse genres intended to inspire, unite and entertain audiences worldwide.

In 2024, City Hill Arts had two films released to critical and audience acclaim, The Secret Art Of Human Flight and My Penguin Friend (currently on VOD and major streaming services). Other projects from CITY HILL ARTS include H Is For Hawk starring Claire Foy and Brendan Gleeson, and the narrative feature Last Days, directed by Justin Lin. Also in post are three documentaries, including How I Faked My Life With AI, Oscar-winner Louis Psihoyos' Tainted Love, and Bucks County, USA from director Barry Levinson. In the Spring of 2025, City Hill Arts is producing and co-financing two films: The Housewife with Naomi Watts and Tye Sheridan, directed by Ben Shirinian and produced by Robbie Brenner; and in May, Rain Reign, starring Paul Rudd and Jeremy Sisto, directed by Erika Burke Rossa.

City Hill Arts was launched in 2022 by serial entrepreneur Jonathan E. Lim who has served as Chairman and/or CEO of six companies in the life sciences (Halozyme, Eclipse, Ignyta, Bonti, Erasca, and Boundless Bio) that have collectively raised over $3 billion and generated more than $10 billion of shareholder value, including consecutive acquisitions of Ignyta by Roche for $1.7 billion and Bonti by Allergan for $260 million in 2018.

Contact:

Steve Elzer
Elzer Kaplan & Co
[email protected]

SOURCE City Hill Arts

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

icon3
440k+
Newsrooms &
Influencers
icon1
9k+
Digital Media
Outlets
icon2
270k+
Journalists
Opted In
GET STARTED

Modal title

Contact PR Newswire

  • Call PR Newswire at 888-776-0942
    from 8 AM - 9 PM ET
  • Chat with an Expert
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices

Products

  • For Marketers
  • For Public Relations
  • For IR & Compliance
  • For Agency
  • All Products

About

  • About PR Newswire
  • About Cision
  • Become a Publishing Partner
  • Become a Channel Partner
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Italy
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom
  • Vietnam

My Services

  • All New Releases
  • Online Member Center
  • ProfNet
  • Data Privacy

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Call PR Newswire at
888-776-0942
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.